Buyers widening their own doors: demand already secured, far-side receiving constraint now being cleared
The model's full reasoning — Q3 2018 call → NOWe need to determine if management conveys that the company already has secured business or demand, but the constraint is the counterparties' ability to receive/absorb it, and that those counterparties are working on that preparation, with business mostly ahead. Let's examine the transcript. Key points: - ICP with Perkin Elmer: co-marketing agreement. Management says "Both companies are committed to this collaboration which has already been demonstrated in various joint efforts." They estimate 2019 revenues from market penetration. But is there already demand? They say "the recent announcement of the relationship with a major industry player, Perkin Elmer." They describe Perkin Elmer as a partner. But is there a description of Perkin Elmer's own ability to receive/install/qualify? They say "Perkin has a robust cell-free DNA extraction offering and ICP was selected by Perkin Elmer as a DNA enrichment technology because together those two elements provide the ideal combination that enables their customers to expand the diagnostic capabilities within their labs to liquid biopsy." This suggests that Perkin Elmer's customers (labs) need to expand their capabilities. But is that described as a constraint? Not explicitly. The constraint is not described as Perkin Elmer's own receiving side. It's more about market penetration. - Pathology services: They have a sales force, growing customer base, revenues growing. They expect continued growth. No mention of counterparties' ability to absorb. - IV-Cell: They mention commercialization with interested parties. "Interested parties -- partners that connected with us received samples of reagent and were able to test the IV-Cell technology in their own laboratory to see it works." That suggests partners are testing, but is there a constraint? Not really. - HemeScreen: They launched internally, and "we've already received numerous orders -- we've already run numerous orders received from physicians." That suggests demand is there, but is there a constraint on the receiving side? No.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| NC | NACCO Industries, Inc. | Q1 2024 | 2024-05-05 | C+ |
| LTRX | Lantronix, Inc. | Q3 2024 | 2024-04-29 | C |
| CTO | CTO Realty Growth, Inc. | Q2 2023 | 2023-07-28 | B |
| BXP | Boston Properties, Inc. | Q1 2022 | 2022-05-03 | A |
| EXP | Eagle Materials Inc. | Q3 2022 | 2022-01-27 | B |
| MKC | McCormick & Company, Incorporated | Q2 2018 | 2018-06-28 | C+ |
| BIIB | Biogen Inc. | Q2 2017 | 2017-07-25 | B |
| PDCO | Patterson Companies, Inc. | Q3 2017 | 2017-02-23 | C |
| ARAY | Accuray Incorporated | Q4 2016 | 2016-08-17 | B |
MKC · Q2 2018 → YESThe question is about whether management conveys that they already have secured business or demand, but the bottleneck is the counterparties' ability to receive, install, etc., and those counterpartie...**NO** The transcript describes a situation where McCormick has already won shelf-space changes and distribution improvements from retailers (customers have accepted the recommendations), but implementation is delayed due to retailers' own operational reset windows and competitor product sell-through. This is framed as a temporary, ongoing industry practice rather than a binding constraint being actively cleared right now to unlock a meaningfully larger volume of already-secured business. Management presents it as part of their category-management progress with runway ahead, not as counterparties clearing a receiving-side bottleneck that is already underway and will drive the bulk of the upside.
BIIB · Q2 2017 → YESThe question is about whether management conveys that they already have secured demand, but the bottleneck is the counterparties' ability to receive/install/etc., and those counterparties are already ...YES The transcript shows management conveying exactly this situation for SPINRAZA. Demand is already secured and arriving: “significant uptake in the U.S.” with “strong demand across patient types” and “roughly two third of patients treated to date having Type 2 or Type 3 SMA.” The binding constraint is on 60% of Type 2 patients who have had spinal surgery, creating intrathecal administration challenges on the receiving side.
BXP · Q1 2022 → YESThe question is about whether management conveys that they already have secured business or demand, but the bottleneck is the counterparties' ability to receive/install/etc., and those counterparties ...YES The transcript shows management conveying secured demand through signed leases totaling over 975,000 square feet on vacant space that have not yet commenced occupancy, plus an additional 1.3 million square feet in active negotiations and over 750,000 square feet in the development pipeline.